Cell MedX Corp (OTCMKTS:CMXC) reported that the firm’s Canadian subsidiary has finalized a production deal with an ISO 9001 marked manufacturing center in Coquitlam, BC, and chosen North American suppliers for obtaining vital components for its eBalance Pro device.
The latest move is planned to enable Cell MedX to support its planned distribution while ensuring lower production expenses and greater control of the production and distribution procedure. Furthermore, it will help the firm with establishing its standard operating processes under ISO 13485-2016, a prerequisite by Health Canada to list the firm’s eBalance Pro device as Class 2 medical device.
Cell MedX’s CEO Frank McEnulty said that their team is extremely thrilled to continue progressing with its strategic plan. The new associations that they secured with the manufacturing facility and with new suppliers is the next major step to bring their eBalance Pro device to industry.
Cell MedX is an early development phase bio-tech firm focused on the discovery, commercialization and development of non-therapeutic and therapeutic products that alleviate complications related with medical ailments including, but not confined to, diabetes, high blood pressure, Parkinson’s disease, and also promote general wellness.
The company is at the important edge in the advancement of devices that treat acute and chronic conditions for both self-management and clinical care. They are advancing safe, results oriented technologies using electro-chemical applications and achieving new levels of treatment, termed as cellular medicine.